Critical Contrast: Jounce Therapeutics (JNCE) and Genocea Biosciences (GNCA)

Share on StockTwits

Jounce Therapeutics (NASDAQ: GNCA) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Jounce Therapeutics and Genocea Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jounce Therapeutics $71.64 million 3.28 -$16.44 million ($0.57) -12.63
Genocea Biosciences $230,000.00 225.99 -$56.71 million ($1.98) -0.30

Jounce Therapeutics has higher revenue and earnings than Genocea Biosciences. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.1% of Jounce Therapeutics shares are owned by institutional investors. Comparatively, 60.2% of Genocea Biosciences shares are owned by institutional investors. 44.0% of Jounce Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Jounce Therapeutics and Genocea Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jounce Therapeutics 0 3 3 0 2.50
Genocea Biosciences 0 1 6 0 2.86

Jounce Therapeutics presently has a consensus target price of $13.20, indicating a potential upside of 83.33%. Genocea Biosciences has a consensus target price of $4.79, indicating a potential upside of 697.62%. Given Genocea Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Jounce Therapeutics.

Volatility and Risk

Jounce Therapeutics has a beta of 5.21, indicating that its share price is 421% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Profitability

This table compares Jounce Therapeutics and Genocea Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics -50.54% -23.27% -11.42%
Genocea Biosciences N/A -780.98% -127.47%

Summary

Jounce Therapeutics beats Genocea Biosciences on 8 of the 14 factors compared between the two stocks.

About Jounce Therapeutics

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply